Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bolt Biotherapeutics Inc
(NQ:
BOLT
)
0.7608
-0.0292 (-3.70%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
193,194
Open
0.8000
Bid (Size)
0.7650 (5)
Ask (Size)
0.8150 (5)
Prev. Close
0.7900
Today's Range
0.7608 - 0.8000
52wk Range
0.7341 - 1.680
Shares Outstanding
8,709,974
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
The Analyst Anxiety Index: 3 Stocks to Avoid as Uncertainty Grows
May 24, 2024
Explore key stocks with analyst uncertainty to avoid amid contrasting global market highs and risky downgrades.
Via
InvestorPlace
Why Bolt Biotherapeutics Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
May 15, 2024
Via
Benzinga
Performance
YTD
-34.41%
-34.41%
1 Month
-36.61%
-36.61%
3 Month
-37.64%
-37.64%
6 Month
-15.47%
-15.47%
1 Year
-49.62%
-49.62%
More News
Read More
12 Health Care Stocks Moving In Wednesday's Intraday Session
May 15, 2024
Via
Benzinga
This Accenture Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Today
May 15, 2024
Via
Benzinga
Why Arcutis Biotherapeutics Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket
May 15, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
May 15, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
May 15, 2024
Via
InvestorPlace
BOLT Stock Earnings: Bolt Biotherapeutics Beats EPS, Beats Revenue for Q1 2024
May 14, 2024
Via
InvestorPlace
12 Health Care Stocks Moving In Tuesday's After-Market Session
May 14, 2024
Via
Benzinga
Bolt Biotherapeutics Reports First Quarter 2024 Results, Announces Strategic Pipeline Prioritization and Changes to Leadership Team
May 14, 2024
From
Bolt Biotherapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
April 03, 2024
Via
Benzinga
BOLT Stock Earnings: Bolt Biotherapeutics Beats EPS, Beats Revenue for Q4 2023
March 21, 2024
Via
InvestorPlace
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
March 21, 2024
From
Bolt Biotherapeutics, Inc.
Via
GlobeNewswire
Bolt Biotherapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
February 27, 2024
From
Bolt Biotherapeutics, Inc.
Via
GlobeNewswire
Pacira Appoints Frank D. Lee as Chief Executive Officer
December 21, 2023
From
Pacira BioSciences
Via
GlobeNewswire
Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®
December 05, 2023
From
Bolt Biotherapeutics, Inc.
Via
GlobeNewswire
Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
November 09, 2023
From
Bolt Biotherapeutics, Inc.
Via
GlobeNewswire
Bolt Biotherapeutics to Present at Stifel 2023 Healthcare Conference
November 07, 2023
From
Bolt Biotherapeutics, Inc.
Via
GlobeNewswire
10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis
October 23, 2023
Via
ACCESSWIRE
Bolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress
October 23, 2023
From
Bolt Biotherapeutics, Inc.
Via
GlobeNewswire
Bolt Biotherapeutics to Present Data at the Society for Immunotherapy of Cancer’s 2023 Annual Meeting
October 18, 2023
From
Bolt Biotherapeutics, Inc.
Via
GlobeNewswire
Bolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced Cancers
October 17, 2023
From
Bolt Biotherapeutics, Inc.
Via
GlobeNewswire
Bolt Biotherapeutics to Present New Clinical Data from Completed Phase 1/2 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Solid Tumors at the ESMO Congress 2023
October 16, 2023
From
Bolt Biotherapeutics, Inc.
Via
GlobeNewswire
Why AERWINS Technologies Shares Are Trading Higher By Around 90%; Here Are 20 Stocks Moving Premarket
October 02, 2023
Via
Benzinga
Bolt Biotherapeutics Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric Cancers
September 28, 2023
From
Bolt Biotherapeutics, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.